A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

GZR102 injection

Participants will get a single dose of GZR102 injection （fixed-ratio combination of GZR4 and GZR18）.

DRUG

GZR4 injection

Participants will get a single dose of GZR4 injection

DRUG

GZR18 injection

Participants will get a single dose of GZR18 injection

Trial Locations (1)

Study site 01, Beijing